Target type: biologicalprocess
Any process involved in the activation of any of the steps of the classical pathway of the complement cascade which allows for the direct killing of microbes, the disposal of immune complexes, and the regulation of other immune processes. [GOC:add, ISBN:0781735149]
The classical pathway of complement activation is triggered by the binding of C1q, the first component of the complement system, to immune complexes containing antibodies (IgG or IgM) bound to antigens. This binding initiates a cascade of proteolytic events leading to the formation of the membrane attack complex (MAC), a pore-forming structure that ultimately results in the lysis of target cells.
Here is a step-by-step description of the classical pathway:
1. **C1q Binding:** C1q, a multimeric protein with globular heads, binds to the Fc portion of antibodies bound to antigens. This binding requires at least two antibody molecules in close proximity, typically in the form of an immune complex.
2. **C1r Activation:** The binding of C1q to an immune complex triggers a conformational change in the C1 complex, activating C1r, a serine protease.
3. **C1s Activation:** Activated C1r then cleaves and activates C1s, another serine protease within the C1 complex.
4. **C4 Cleavage:** Activated C1s cleaves C4, a complement protein, into two fragments: C4a and C4b. C4b binds to the cell surface near the antibody-antigen complex, forming a C4b-antigen complex.
5. **C2 Cleavage:** C1s also cleaves C2, another complement protein, into C2a and C2b. C2a binds to C4b, forming a C4b2a complex, known as the classical pathway C3 convertase.
6. **C3 Cleavage:** The C3 convertase cleaves C3, a central component of the complement system, into C3a and C3b. C3b binds to the cell surface, forming a C4b2a3b complex, also known as the classical pathway C5 convertase.
7. **C5 Cleavage:** The C5 convertase cleaves C5, another complement protein, into C5a and C5b.
8. **MAC Formation:** C5b binds to the cell surface and initiates the assembly of the membrane attack complex (MAC). C6, C7, C8, and multiple copies of C9 bind to C5b, forming a pore in the cell membrane. This pore disrupts the cell membrane, leading to cell lysis.
9. **Anaphylatoxins:** The cleavage products C3a and C5a are known as anaphylatoxins, which trigger inflammatory responses by binding to specific receptors on mast cells, basophils, and neutrophils.
The classical pathway is an important part of the innate immune system, providing a rapid and effective defense against pathogens. It is also involved in the clearance of immune complexes and the regulation of immune responses.'
"
Protein | Definition | Taxonomy |
---|---|---|
Complement C1r subcomponent | A complement C1r subcomponent that is encoded in the genome of human. [PRO:DNx, UniProtKB:P00736] | Homo sapiens (human) |
Complement C1s subcomponent | A complement C1s subcomponent that is encoded in the genome of human. [PRO:DNx, UniProtKB:P09871] | Homo sapiens (human) |
Complement component C9 | A complement component C9 that is encoded in the genome of human. [PRO:DNx, UniProtKB:P02748] | Homo sapiens (human) |
Complement C5 | A complement C5 that is encoded in the genome of human. [PRO:DNx, UniProtKB:P01031] | Homo sapiens (human) |
Complement C3 | A complement C3 that is encoded in the genome of human. [UniProtKB:P01024] | Homo sapiens (human) |
Complement C1r subcomponent | A complement C1r subcomponent that is encoded in the genome of human. [PRO:DNx, UniProtKB:P00736] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
pimagedine | aminoguanidine : A one-carbon compound whose unique structure renders it capable of acting as a derivative of hydrazine, guanidine or formamide. pimagedine: diamine oxidase & nitric oxide synthase inhibitor; an advanced glycosylation end product inhibitor; used in the treatment of diabetic complications; structure | guanidines; one-carbon compound | EC 1.14.13.39 (nitric oxide synthase) inhibitor; EC 1.4.3.4 (monoamine oxidase) inhibitor |
aurintricarboxylic acid | aurintricarboxylic acid : A member of the class of quinomethanes that is 3-methylidene-6-oxocyclohexa-1,4-diene-1-carboxylic acid in which the methylidene hydrogens are replaced by 4-carboxy-3-hydroxyphenyl groups. The trisodium salt is the biological stain 'chrome violet CG' while the triammonium salt is 'aluminon'. Aurintricarboxylic Acid: A dye which inhibits protein biosynthesis at the initial stages. The ammonium salt (aluminon) is a reagent for the colorimetric estimation of aluminum in water, foods, and tissues. | monohydroxybenzoic acid; quinomethanes; tricarboxylic acid | fluorochrome; histological dye; insulin-like growth factor receptor 1 antagonist |
carprofen | carprofen : Propanoic acid in which one of the methylene hydrogens is substituted by a 6-chloro-9H-carbazol-2-yl group. A non-steroidal anti-inflammatory drug, it is no longer used in human medicine but is still used for treatment of arthritis in elderly dogs. carprofen: RN given refers to cpd without isomeric designation | carbazoles; organochlorine compound | EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-steroidal anti-inflammatory drug; photosensitizing agent |
nafamostat | nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic | benzoic acids; guanidines | |
oxaprozin | oxaprozin : A monocarboxylic acid that is a propionic acid derivative having a 4,5-diphenyl-1,3-oxazol-2-yl substituent at position 3. It is non-steroidal anti-inflammatory drug commonly used to relieve the pain and inflammatory responses associated with osteoarthritis and rheumatoid arthritis. Oxaprozin: An oxazole-propionic acid derivative, cyclooxygenase inhibitor, and non-steroidal anti-inflammatory drug that is used in the treatment of pain and inflammation associated with of OSTEOARTHRITIS; RHEUMATOID ARTHRITIS; and ARTHRITIS, JUVENILE. | 1,3-oxazoles; monocarboxylic acid | analgesic; non-steroidal anti-inflammatory drug |
raloxifene | raloxifene : A member of the class of 1-benzothiophenes that is 1-benzothiophene in which the hydrogens at positions 2, 3, and 6 have been replaced by p-hydroxyphenyl, p-[2-(piperidin-1-yl)ethoxy]benzoyl, and hydroxy groups, respectively. | 1-benzothiophenes; aromatic ketone; N-oxyethylpiperidine; phenols | bone density conservation agent; estrogen antagonist; estrogen receptor modulator |
phenylguanidine | phenylguanidine: RN given refers to parent cpd | ||
sepimostate mesilate | sepimostate mesilate: used in therapy of pancreatitis; structure given in first source | ||
2-guanidine-4-methylquinazoline | 2-guanidine-4-methylquinazoline: structure given in first source | ||
benzamidine | carboxamidinium ion | ||
sulindac | sulindac : A monocarboxylic acid that is 1-benzylidene-1H-indene which is substituted at positions 2, 3, and 5 by methyl, carboxymethyl, and fluorine respectively, and in which the phenyl group of the benzylidene moiety is substituted at the para position by a methylsulfinyl group. It is a prodrug for the corresponding sulfide, a non-steroidal anti-inflammatory drug, used particularly in the treatment of acute and chronic inflammatory conditions. Sulindac: A sulfinylindene derivative prodrug whose sulfinyl moiety is converted in vivo to an active NSAID analgesic. Specifically, the prodrug is converted by liver enzymes to a sulfide which is excreted in the bile and then reabsorbed from the intestine. This helps to maintain constant blood levels with reduced gastrointestinal side effects. | monocarboxylic acid; organofluorine compound; sulfoxide | analgesic; antineoplastic agent; antipyretic; apoptosis inducer; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug; prodrug; tocolytic agent |
compstatin | compstatin: binds to complement 3; amino acid sequence in first source |